中国内科肿瘤学奠基人孙燕去世，肿瘤界纷纷撰文纪念

Core Viewpoint - Sun Yan, a pioneer in China's oncology field, passed away at the age of 97, leaving a significant legacy in cancer treatment and research [2]. Group 1: Contributions to Oncology - Sun Yan was a founding figure in the development of oncology in China, advocating for a comprehensive treatment approach and leading the establishment of the discipline from scratch [2]. - He initiated nearly 80 clinical trials and trained over a thousand oncology professionals, significantly contributing to the growth of the field [2]. - Sun Yan was involved in the development of over 30 new drugs, including the first small-molecule targeted anti-cancer drug in China, demonstrating his impact on drug innovation [2]. Group 2: Recognition and Awards - Throughout his career, Sun Yan received numerous accolades, including the National Science and Technology Progress Award (First Class) and the Chinese Physician Award, highlighting his contributions to medical science [2][5]. - He was elected as an academician of the Chinese Academy of Engineering in 1999, further solidifying his status in the medical community [2]. Group 3: Legacy and Influence - Following his passing, many in the oncology community expressed their condolences and shared memories, emphasizing his role in founding the Chinese Society of Clinical Oncology (CSCO) and fostering international collaboration [3]. - His efforts in organizing national cancer cause investigations and creating the first "Malignant Tumor Atlas" were pivotal in advancing the understanding of cancer in China [3]. - Sun Yan's dedication to education and mentorship has left a lasting impact, with many professionals in the field crediting him for their foundational training and guidance [4][5].